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ABSTRACT  
Background: Alcohol-related cerebellar degeneration is one of the commonest 
acquired forms of cerebellar ataxia. The exact pathogenic mechanisms by 
which alcohol leads to cerebellar damage remain unknown. Possible 
autoreactive immune immediate mechanisms have not been explored 
previously. In this study, we aim to investigate the potential role of alcohol-
induced immune mediated cerebellar degeneration.  
Methods: Patients with ataxia and a history of alcohol misuse were recruited 
from the Ataxia and Hepatology tertiary clinics at Sheffield Teaching Hospitals 
NHS Trust. We determined the pattern of cerebellar involvement both on 
clinical (SARA score) and imaging (MRI volumetry and MR spectroscopy) 
parameters. In addition, HLA genotyping, serological markers for gluten-related 
disorders and serological reactivity on rat cerebellar tissue using indirect 
immunohistochemistry were assessed.  
Results: Thirty-eight patients were included in the study all of whom had ataxia. 
The gait (97%), stance (89%) and heel-shin slide (89%) were the predominant 
SARA elements affected. MRI volumetric and spectroscopy techniques 
demonstrated significant structural, volumetric and functional deficits of the 
cerebellum with particular involvement of the cerebellar vermis. Circulating anti-
gliadin antibodies were detected in 34% patients vs. 12% in healthy controls. 
Antibodies to transglutaminase 6 (TG6) were detected in 39% of patients and 
4% of healthy control subjects. Using immunohistochemistry, Purkinje cell and 
/ or granular layer reactivity was demonstrated in 71% of patient sera.  
  Shanmugarajah 
 
5 
Conclusions: Alcohol induced tissue injury to the CNS leading to cerebellar 
degeneration may also involve immune mediated mechanisms, including 
sensitisation to gluten. 
 
Keywords 
Alcohol, ataxia, cerebellum, cerebellar degeneration, transglutaminase 
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BACKGROUND 
Alcohol misuse is recognized worldwide as a major cause of morbidity and 
mortality with significant health and economic consequences. The toxic effects 
of alcohol are diverse. Alcohol-related cerebellar degeneration is one of the 
commonest causes of acquired cerebellar ataxia. The pathophysiology remains 
unclear but proposed mechanisms include excitotoxicity, dietary factors, 
oxidative stress, compromised energy production and cell death(1). Some 
argue that the direct toxic effects of alcohol on cerebellar cells is responsible, 
whilst others report that nutritional factors particularly thiamine deficiency are 
required to drive the underlying process(2).  
 
Cerebellar atrophy is a recognised result of alcohol-related cerebellar 
degeneration. The anterior superior cerebellar vermis is predominantly 
affected(3, 4) with the Purkinje cell, granular and white matter layers being most 
susceptible(2). This has been confirmed in large autopsy studies(5, 6). MRI 
findings of vermian atrophy, with preferential involvement of the lingula(7), are 
in keeping with the neuropathological findings.  
 
Metabolic deficits can be demonstrated by magnetic resonance (MR) 
spectroscopy, with low N-acetyl aspartate:creatine ratio (NAA/Cr) in the 
cerebellar vermis.  MR Spectroscopy can directly detect ethanol by a triple peak 
at 1.3 ppm(8). Chronic alcohol use causes a reduction in NAA and choline 
levels compared to healthy controls; thus MR spectroscopy provides a useful 
tool for monitoring cerebellar function.  
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Chronic alcohol use has been shown to provoke an IgA response that is not 
only directed towards alcohol metabolites but also against self antigens, 
targeting the enzyme transglutaminase 2 (TG2), even in the absence of liver 
disease(9). Transglutaminases are a widely distributed family of enzymes with 
cross-linking capability that aid tissue repair(10). TG2 is the autoantigen in 
coeliac disease. However, autoimmunity to TG2 can also precipitate hepatitis 
and ultimately liver failure(11). Proposed mechanisms for the high prevalence 
of TG2 autoantibodies in patients with chronic alcohol abuse include increased 
gut permeability associated with alcohol induced intestinal mucosal lesions(9) 
leading to increased exposure of the immune system to pathogenic antigens 
(including gluten peptides). In line with this, alcohol has been shown to induce 
sensitisation to gluten in genetically susceptible individuals(12).  
 
The aim of this study was to investigate further a potential link between 
autoreactive immune responses and cerebellar degeneration in the context of 
excessive alcohol intake.  
 
METHODS 
Subject selection and clinical assessments 
The study was approved by the regional ethics committee (Yorkshire & The 
Humber, UK). Written informed consent was obtained from all patients.  
Patients were recruited from the Ataxia and Hepatology outpatient clinics at the 
Royal Hallamshire Hospital, Sheffield, UK. Patients included were grouped as 
‘alcohol ataxia (AA)’ and had a history of chronic ‘alcohol dependence’, defined 
by the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders 
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(DSM-IV) Diagnostic Criteria for Alcohol Abuse and Dependence(13). A 
subgroup of patients with alcohol-related ‘chronic liver disease’ (defined as 
alcohol related liver disease diagnosed by a hepatologist and disease present 
for more than 1 year) and ataxia (CLDA) was identified from this patient group.  
 
Detailed neurological history and any background history of autoimmune 
disorders were recorded, as were age at onset, duration of ataxia, requirement 
for mobility aids, and current alcohol intake or abstinence at the time of 
recruitment. 
 
Detailed neurological examination was performed. Ataxia was classified as gait, 
limb or both and severity was assessed as mild (mobilising independently or 
with one walking aid), moderate (mobilising with 2 walking aids or walking 
frame) or severe (wheelchair-dependent). The severity assessment was 
adapted and modified from previously published data(14). Objective 
measurement of the severity of ataxia was rated using the Scale for the 
Assessment and Rating of Ataxia (SARA)(15, 16) (see supplementary 
material). All patients were investigated for other causes of ataxia and were 
excluded if an alternative cause was found. Tests depending on clinical 
indications included blood cell counts, biochemistry, thyroid function, B12, 
folate and genetic testing for inherited spinocerebellar ataxias (SCA 1, 2, 3, 6, 
7) and Friedreich’s ataxia (FA). 
 
Brain imaging 
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Volumetric 3T MR imaging and single-voxel H1 MR spectroscopy of the 
cerebellum were undertaken in patients with clinical evidence of ataxia. This 
imaging protocol is in clinical use as part of the investigations of all patients with 
cerebellar ataxia who attend the National Ataxia Centre in the Royal 
Hallamshire Hospital, Sheffield, UK. The brain imaging protocol for structural, 
volumetric and spectroscopy studies have been previously reported(12).  
 
The vermis was assessed as a whole for volumetric analysis. A manual 
approach was adopted for volumetric analysis of the vermis to avoid partial 
volume averaging effects that may also be affected by the degree of atrophy 
potentially confounding VBM results (unpublished data). For vermian 
volumetric studies, the midline vermis was identified on sagittal T1 volume 
images with reference to the midsagittal plane of the cerebellum(17). Based on 
this reference, manual measurement of cross sectional areas of the whole 
vermis was possible. Vermian volume (V) in mm3 was measured as a sum of 
vermis cross sectional areas (mm2) multiplied by 0.9mm thickness. Vermian 
volume was expressed as a percentage of the total intracranial volume 
(%V:TIV). 
 
Healthy controls recruited, were age and gender matched with patient subjects 
and had undergone the same MR Imaging protocol. The details of the healthy 
controls have also been previously reported(18).  
 
Blood collection and serological tests  
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Blood samples were collected at recruitment and the serum was aliquoted to 
avoid repeat freeze-thawing and stored at -20° C in sealed tubes.  
 
All patients had total immunoglobulin levels, IgA and IgG anti-gliadin antibodies 
(AGA), anti-endomysial antibodies (EMA) and IgA anti-transglutaminase 2 
(TG2) antibodies, measured by standard laboratory protocols at the 
Immunology Department, Northern General Hospital, Sheffield. Briefly, the 
measurement for AGA and TG2 were performed by enzyme linked 
immunosorbent assay (ELISA) (Aesku. Diagnostics-Grifols, Germany). EMA 
was tested by indirect immunofluorescence on slides containing monkey 
oesophagus tissue (Inova-Instrumentation Laboratories, USA). Patient sera 
were also used for the detection of IgA and IgG to transglutaminase 6 (TG6) by 
ELISA as previously described(19).  
 
Human Leukocyte Antigen (HLA) typing was performed at the National Blood 
Service, Sheffield, UK. 
 
Immunohistochemistry 
Rat cerebellar tissue was acquired from adult Sprague-Dawley rats (Biological 
Services, Faculty of Medicine, Dentistry & Health, University of Sheffield). The 
cerebellar tissue was mounted using Cryo-M-Bed tissue embedding polymer 
(Bright, UK) and snap-frozen with isopentane / cooled on liquid nitrogen. The 
cerebellar tissue was cryo-sectioned into 10m sagittal sections that were 
collected on polysine-coated slides (Thermo Scientific, UK), stored at -80 C in 
an airtight container. 
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Mouse anti-calbindin-D-28K monoclonal antibody (Sigma, UK) diluted 1:200 in 
PBS was used to visualize Purkinje cells. Patient sera were diluted 1:200 or 
1:600 in PBS before incubation with sections for 1h. 1:600 was identified as the 
optimum dilution in determining the reactivity of patient sera on rat cerebellar 
tissue in agreement with our previous study(20).  Negative controls included 
sections incubated without patient sera. A horseradish peroxidase-conjugated 
goat anti-human or goat anti-mouse IgG antibody (Jackson ImmunoResearch 
Laboratories, USA) was used as secondary antibodies. 
 
Images were captured at X100 and X200 magnification. Two blinded observers 
performed the evaluation of the Purkinje cell staining intensity on rat cerebellar 
sections independently. Staining was classed as ‘weak’ or ‘strong’ if Purkinje 
cell staining was above background levels. ‘Negative’ was recorded if staining 
did not exceed background levels. Staining of other neuronal cell populations 
(granular layer) was also noted. Concordance rate between assessors was 
79%. 
  
Statistical analysis 
Statistical analysis was performed using PRISM 6 software package 
(GraphPad Software Inc.). Demographic, clinical and imaging characteristics 
are presented as means with standard deviations (mean ± SD). The 
Independent-Samples Mann-Whitney U Test was used to determine any 
difference between mean % cerebellar volume (CBV) : total intracranial volume 
(TIV) and mean % vermian volume (V) : total intracranial volume (TIV) between 
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patients and controls. The 2 test was used for comparing the prevalence of 
anti-gliadin antibodies and anti-transglutaminase 6 antibodies in the study 
group with that of the healthy population; and between the subgroups. Results 
were considered statistically significant for p < 0.05.  
 
RESULTS 
Clinical presentation 
Thirty-eight patients were recruited with mean age of 54 ± 10 years. There were 
31 male and 7 female patients. All patients had clinical evidence of ataxia. Thirty 
of the 38 (79%) patients were grouped as ‘alcohol ataxia’ (AA) as ataxia was 
their presenting complaint. A  further group of 8/38 (21%) patients recruited 
from the Hepatology clinics, were selected on the basis of having alcohol-
related chronic liver disease, but were also found to have ataxia, hence 
categorised as ‘chronic liver disease and ataxia’ (CLDA). Fourteen patients 
(37%) had been abstinent from alcohol consumption at the time of recruitment. 
A background of autoimmune history (diabetes (2), thyroid disorder (1), 
pernicious anaemia (4)) was seen in 7/38 (18%) patients.  
 
Age of ataxia onset was 49 ± 11 years. Duration of ataxia ranged from one to 
27 years (Mean 6 ± 5 years). Pure gait ataxia was found in 4/38 (11%) patients 
and the majority of 34/38 (89%) patients had both gait and limb ataxia. 
Nystagmus was present in 11/38 (29%) patients.  
 
Forty seven percent had mild ataxia (mobilising independently or with one 
walking aid). Moderate ataxia was seen in 34% and severe ataxia was seen in 
18% patients. There was no difference in the autoimmune profile between 
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patients with mild, moderate or severe ataxia. The severity of ataxia using the 
SARA scale revealed a mean total SARA score of 12 ± 7 (range 1 to 26). There 
was a correlation seen between duration of ataxia and total SARA score (p 
0.0272). 
 
Table 1 demonstrates the frequency of involvement for each of the eight key 
SARA elements. The gait (97%), stance (89%) and heel-shin slide (89%) were 
the predominant SARA elements affected.  
 
 
Table 1 Scale for the assessment and rating of ataxia (SARA) in patients with                                   
alcohol ataxia 
SARA elements AA CLDA Total 
Gait 29/30 (97%) 8/8 (100%) 37/38 (97%) 
Stance 26/30 (87%) 8/8 (100%) 34/38 (89%) 
Sitting 5/30 (17%) 0/8 (0%) 5/38 (13%) 
Speech disturbance 10/30 (33%) 1/8 (13%) 11/38 (29%) 
Finger chase 15/30 (50%) 5/8 (63%) 20/38 (53%) 
Nose-finger test 17/30 (57%) 5/8 (63%) 22/38 (58%) 
Fast alternating 
hand movements 
18/30 (60%) 6/8 (75%) 24/38 (63%) 
Heel-shin slide 27/30 (90%) 7/8 (88%) 34/38 (89%) 
 
 
Brain imaging 
MR Spectroscopy was performed in 34 patients. Data analysis was based on 
32 (25 AA and 7 CLDA) optimal scans. Two scans were excluded as they were 
of inadequate quality. Abnormal NAA/Cr area ratio (vermis NAA/Cr area ratio < 
0.95 and/or hemisphere NAA/Cr < 1.00)(21) was recorded in 29/32 (91%) 
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patients. This included 22/25 (88%) patients with AA and 7/7 (100%) patients 
with CLDA. 
 
Predominantly vermian abnormalities were present in 18/25 (72%) patients with 
AA and 6/7 (86%) patients with CLDA. The hemisphere was solely affected in 
only 4/25 (16%) patients with AA and 1/7 (14%) patients with CLDA.  
 
Volumetric Image analysis matched for age and gender with healthy controls 
was possible in 28 patients (22 patients with AA and 6 patients with CLDA). 
Results are displayed as a whole group (AA and CLDA) vs. controls. Cerebellar 
volume (%CBV:TIV) was significantly smaller (8.68 ± 0.99) in this study group 
when compared with age and gender matched healthy controls (9.57 ± 0.96); 
CI 95% 8.29 to 9.06, p 0.0027. Similarly, vermian volume (%V:TIV) was 
significantly smaller in the study group (1.13 ± 0.24) when compared to age and 
gender matched healthy controls (1.34 ± 0.13); CI 95% 1.03 to 1.22, p 0.0003. 
 
There was no significant correlation seen between total SARA score and brain 
imaging measures. 
 
Serological testing for gluten-related antibodies 
Normal total serum immunoglobulins were seen in 21/38 (55%) patients. 
Raised IgA levels were seen in 8/38 (21%) patients. 
 
Circulating anti-gliadin antibodies were detected in 13/38 (34%) patients (8 AA 
and 5 CLDA) compared with a 12% prevalence in healthy controls(22) (2 p 
0.012). The difference between the AA and CLDA groups was not statistically 
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significant. Circulating anti-transglutaminase 2 (TG2) antibodies were 
demonstrated in 4/38 (11%) patients, (3 AA and 1 CLDA). The three AA patients 
had low TG2 titres and the one CLDA patient had TG2 titres >300 U/mL. No 
patients tested positive for EMA. 
 
Antibodies to transglutaminase 6 (TG6) were detected in 15/38 (39%) patients 
vs. 4% in healthy controls(23) (2 p <0.0001). The 15 patients with anti-TG6 
antibodies included 9/30 (30%) patients with AA and 6/8 (75%) patients with 
CLDA (2 p 0.0207). Thirteen of the 15 patients had IgA anti-TG6 antibodies, 
one had IgG anti-TG6 antibodies and one patient had both IgA and IgG anti-
TG6 antibodies.  
 
HLA genotyping for DQ2 / DQ8 
Eighteen of the 38 (47%) patients in the study group had HLA type DQ2 or 
DQ8. This was not significantly different from the healthy population of 30%(24) 
(p 0.056). There was no significant difference between any subgroup (AA vs. 
CLDA), using the 2 test. 
 
Serum reactivity with neural tissue 
Three specific staining patterns were identified (pure Purkinje cell, pure 
granular layer and combined Purkinje cell and granular layer staining pattern) 
when rat brain sections were incubated with patient sera (see supplementary 
material). In 27/38 (71%) patients, one of these patterns was present. 
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Pure Purkinje cell (PC) staining was demonstrated in 4/38 (11%) patients. This 
included 3/30 (10%) patients with AA and 1/8 (13%) patients with CLDA. Pure 
granular layer staining was demonstrated in 16/38 (42%) patients. This 
included 12/30 (40%) patients with AA and 4/8 (50%) patients with CLDA. 
Combined Purkinje cell and granular layer staining was demonstrated in 7/38 
(18%) patients that included 5/30 (17%) patients with AA and 2/8 (25%) patients 
with CLDA. 
 
Overall, Purkinje cell reactivity was seen in 11/38 (29%) of patients and granular 
layer reactivity in 23/38 (61%) patients. There was no statistically significant 
difference in prevalence of Purkinje cell and / or granular layer staining between 
the 2 subgroups.  
 
Based on the same methodology, our previous studies did not demonstrate any 
staining in healthy controls and showed only 5% staining in patients with genetic 
ataxia(20, 25). Table 2. summarises the serological characteristics of patients 
with alcohol ataxia. 
 
DISCUSSION 
In this study, we investigated whether an autoimmune process may drive 
alcohol-induced cerebellar damage. Our initial intention was to study patients 
with alcoholic liver disease without ataxia and a subgroup of patients who 
presented with alcohol-induced ataxia. However, all patients with alcoholic liver 
disease were found to also have ataxia thus a subgroup of patients with ‘chronic 
liver disease and ataxia’ was defined. This division into 2 subgroups is 
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somewhat arbitrary as patients with alcohol-induced ataxia almost always have 
some degree of liver involvement (demonstrated by elevated levels of gamma 
GT). Given the overlap in functional deficits, our sample size would also be too 
small to make any definitive conclusions on specific differences between the 2 
subgroups. Nonetheless, we still studied the 2 subgroups given the distinct 
differences in presentation.  
 
Imaging data using MRI volumetric and spectroscopy techniques demonstrated 
significant structural and functional deficits of the cerebellum, with preferential 
involvement of the cerebellar vermis. There was significant vermian volume 
loss in patients with alcohol ataxia compared to age and gender matched 
healthy controls. The findings support neuropathological data that alcohol-
related cerebellar degeneration preferentially affects the cerebellar vermis (2-
7). Vermian involvement is common in immune-mediated ataxias such as 
gluten ataxia, paraneoplastic cerebellar degeneration and primary autoimmune 
cerebellar ataxia(26). We did not find any correlation between the imaging 
findings and the serological and immunohistochemical findings in this cohort. 
The sample size, however, may be a contributory factor to this. 
 
Alcohol excess is associated with impairment of the blood-brain barrier. The 
oxidative stress caused by alcohol metabolism on brain microvascular 
endothelial cells by activation of myosin light chain kinase leads to disruption of 
the tight junctions inducing blood-brain barrier breakdown(27, 28). This 
enhanced permeability may lead to neo-epitope exposure to the immune 
system and thereby induction of autoimmune responses to these neo-epitopes 
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or allow reaction of serum antibodies with neural tissue and consequently 
trigger localized inflammatory processes in the brain. In line with this, we show 
that 71% of patients with alcohol ataxia have circulating antibodies that react 
with neural tissue. Three cerebellar staining patterns were seen when rat brain 
sections were incubated with patient sera: pure Purkinje cell (11%), pure 
granular layer (42%) and combined Purkinje cell and granular layer (18%). We 
have previously shown that up to 60% of patients with idiopathic sporadic ataxia 
have anti-cerebellar antibodies as opposed to 5% of patients with genetic 
ataxia(25). It is possible that alcohol is a contributing factor to “idiopathic” 
sporadic ataxia, or that similar immune-mediated processes can be triggered 
by infection or other unrelated environmental factors in addition to alcohol. 
 
Increased gut permeability and mucosal damage are typical clinical findings in 
patients with alcohol misuse. Not surprisingly, this may trigger a breakdown in 
immune tolerance and autoimmune responses in patients harbouring genetic 
susceptibility (HLA DQ2/DQ8). Excessive alcohol intake is a risk factor for 
coeliac disease development(9, 12). TG2 IgA autoantibody titres have been 
reported to positively correlate with liver disease(9) which is in accordance with 
the view that liver disease per se may be associated with the occurrence of 
TG2 autoantibodies(11). The role of TG in tissue repair and its deposition into 
the extracellular matrix(29) may lead to abundant autoantibody binding and 
thereby drive chronic inflammation and fibrogenesis. Only one of the patients 
examined here had high levels of circulating anti-TG2 autoantibodies 
suggesting that coeliac disease is not a primary underlying mechanism in this 
cohort selected on the basis of neurological deficits. However, in gluten-related 
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disorders with extraintestinal manifestation, particularly neurological, 
enteropathy may not be present and autoantibodies to TG2 may not be 
detectable in the circulation(19, 23).  
 
It is therefore of interest that firstly, we found a significantly higher prevalence 
of anti-gliadin antibodies in the study group (34%) compared to healthy controls 
(12%) and secondly that we found a significantly higher prevalence of anti-TG6 
antibodies in the study group (39%) compared to healthy control subjects (4%). 
Circulating anti-TG6 antibodies are the best marker currently available for 
patients with primarily neurological presentation of gluten-related disorders(23). 
However, their prevalence in the study group was not substantially different to 
what we previously reported for idiopathic ataxia (32%), and the association of 
AGA and anti-TG6 autoantibodies is in line with previous findings (gluten 
ataxia)(23). Clearly, these antibodies alone cannot explain the serum reactivity 
to the granular layer neurons in most of these patients(20, 30). Anti-TG6 
antibodies were more prevalent in the subgroup of patients with CLDA (75%) 
compared to the subgroup of patients with AA (30%) suggesting that alcohol-
related chronic liver disease itself may be another risk factor for the 
development of autoimmunity to TG6. It remains to be shown where the 
immune response to TG6 develops. The fact that almost exclusively an IgA 
response was seen makes the gastrointestinal tract a likely candidate.  
 
CONCLUSIONS 
Taken together, these results suggest that factors other than direct cellular 
toxicity from alcohol, including autoimmune responses, may play a part in 
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cerebellar degeneration in patients with alcohol ataxia. The role of gluten 
sensitivity merits further exploration but the findings of this and previous studies 
suggest that sensitivity to gluten may be an epiphenomenon, likely resulting 
from increased gut permeability. Development of gluten-related autoantibodies, 
however, may perpetuate cerebellar degeneration even when the patient 
abstains from alcohol intake. If that proves to be the case, a gluten free diet 
may prove to be beneficial for such patients. 
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Table 2 Serological characteristics of patients with alcohol ataxia 
Patient 
ID 
Gender 
Age at 
study, 
y 
HLA 
DQ2/DQ8 
Antigliadin 
IgA and/or 
IgG 
Anti-TG6 
PC 
stained 
GL 
stained 
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IgA 
and/or 
IgG 
8 M 33 DQ2  IgA  + 
9* M 41     + 
20 M 50 DQ8   + ++ 
27 M 67     ++ 
28 M 56  IgA  + + 
30* M 46     + 
31 M 50    ++ + 
32 M 66   IgA ++ + 
33 M 58 DQ8     
37 M 53 DQ2 IgA   + 
38 F 56  IgA   + 
45 M 49 DQ8    + 
47 F 60  IgA    
49* M 51 DQ8 IgA, IgG IgA   
55 F 48 DQ2   +  
62 M 41      
69 M 58      
92 M 64 DQ8   ++ + 
100 M 55 DQ2  IgA   
101 F 49 DQ2    + 
103 F 48 DQ8 IgA   + 
104 M 55 DQ2    + 
107* M 46 DQ2 IgA IgA ++ ++ 
116 M 51 DQ8  IgG  ++ 
119 M 48   IgA  ++ 
120* M 50   IgA  + 
121 M 45     + 
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122* M 50  IgA IgA  + 
125 F 66 DQ2  IgA   
128 M 68 DQ2  IgA   
132 M 62      
133* M 59 DQ2 IgA IgA + ++ 
134 F 58    +  
135 M 57  IgA IgA +  
136* M 47  IgA IgA +  
139 M 65 DQ2 IgA, IgG IgA, IgG   
143 M 67  IgG    
145 M 81     + 
* = subgroup chronic liver disease and ataxia (CLDA), y = years, TG6 = transglutaminase 6  
PC = Purkinje cell layer, GL = Granular layer, + = weak staining, ++ = strong staining  
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